MapLight Therapeutics (MPLT) Accounts Payables (2024 - 2025)
MapLight Therapeutics (MPLT) reported Accounts Payables of $3.3 million for Q4 2025, up 72.02% on a YoY basis from $1.9 million in Q4 2024, and up 34.46% sequentially from $2.4 million in Q3 2025.
MapLight Therapeutics (MPLT) Accounts Payables (2024 - 2025) Analysis & Trends
MapLight Therapeutics (MPLT) has 2 years of Accounts Payables data on file, last reported at $3.3 million in Q4 2025.
- For the quarter ending Q4 2025, Accounts Payables rose 72.02% year-over-year to $3.3 million; the trailing twelve-month figure through Dec 2025 stood at $3.3 million (up 72.02% YoY), and the FY2025 full-year result was $3.3 million, up 72.02% from the prior year.
- Accounts Payables improved to $3.3 million in Q4 2025, from $2.4 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $3.3 million in Q4 2025 to a low of $1.9 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 10.62 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 423.55 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 694,346.76 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.52 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 80.54 Mn |
| 10 | MapLight Therapeutics | 305.82 Mn | 305.82 Mn | - | 3.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.29 Mn |
| Sep 30, 2025 | 2.45 Mn |
| Dec 31, 2024 | 1.91 Mn |